We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Cyclooxygenase Inhibitors Decrease Antibody Response to Vaccination

By LabMedica International staff writers
Posted on 23 Dec 2009
The effectiveness of vaccination may be significantly diminished if the individual receiving the vaccine has been treated with an inhibitor of cyclooxygenase-1 (COX-1), which also causes a drop in the production of interleukin-17 (IL-17).

The COX enzymes are known modulators of innate immune cell function; however, their contributions to adaptive immunity (antibody production) are relatively unknown. More...
Therefore, investigators at the University of Missouri (Columbia, USA) studied the roles of COX-1 and COX-2 in the humoral immune response to infection with the Lyme disease pathogen Borrelia burgdorferi.

The investigators reported in the November 1, 2009, issue of The Journal of Immunology that in vitro, mouse B cells expressed COX-1 at a constant rate, but upregulated expression of COX-1 and COX-2 as well as their products PGE2, PGF2-alpha, and thromboxane B2, and their receptors following stimulation with B. burgdorferi. In vitro inhibition of COX-1 and/or COX-2 resulted in decreased eicosanoid production and altered antibody production. Importantly, infection of mice lacking COX-1, but not COX-2, activity resulted in a defect in immunoglobulin class switching and a lack of Borrelia-specific IgG production. This defect correlated with decreased IL-6 and IL-17 production, and it could be partially recovered by restoration of IL-6, but fully recovered by IL-17.

Furthermore, sera from COX-1 inhibitor-treated mice were dramatically less effective in killing B. burgdorferi, but borreliacidal activity was restored in COX-1 inhibitor-treated mice administered IL-17. Thus, IL-17 plays a role in antibody production and immunoglobulin class switching in response to infection, and that COX-1 is a critical, previously unrecognized regulator of this response.

"If you are taking aspirin regularly, which many people do for cardiovascular treatment, or acetaminophen for pain and fever and get a flu shot, there is a good chance that you will not have a good antibody response,” said senior author Dr. Charles Brown, associate professor of veterinary pathobiology at the University of Missouri. "These drugs block the enzyme COX-1, which works in tissues throughout the body. We have found that if you block COX-1, you might be decreasing the amount of antibodies your body is producing, and you need high amounts of antibodies to be protected.”

"So far, we have tested this on an animal model and have found that these nonsteroidal drugs do inhibit vaccines, but the next step is to test it on humans,” said Dr. Brown. "If our results show that COX-1 inhibitors affect vaccines, the takeaway might be to not take drugs, such as aspirin, acetaminophen, and ibuprofen for a couple weeks before and after you get a vaccine.”

Related Links:
University of Missouri


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.